

**NSABP Protocol B-28: Characteristics of Patients
for whom Pathology Material is Available for Study**

	AC Only		AC+Taxol		All	
	No.	(%)	No.	(%)	No.	(%)
Age						
≤39	124	(13.0)	148	(14.9)	272	(13.9)
40-49	343	(35.9)	349	(35.1)	692	(35.5)
50-59	307	(32.1)	304	(30.6)	611	(31.3)
≥60	182	(19.0)	194	(19.5)	376	(19.3)
Race						
White	817	(85.5)	843	(84.7)	1660	(85.1)
Black	80	(8.4)	84	(8.4)	164	(8.4)
Other	55	(5.8)	66	(6.6)	121	(6.2)
Unknown	4	(0.4)	2	(0.2)	6	(0.3)
Clinical Tumor Size (cm)						
≤2.0	558	(58.4)	563	(56.6)	1121	(57.5)
2.1-4.0	326	(34.1)	340	(34.2)	666	(34.1)
≥4.1	70	(7.3)	91	(9.1)	161	(8.3)
Unknown	2	(0.2)	1	(0.1)	3	(0.2)
No. of Positive Nodes						
1-3	670	(70.1)	696	(69.9)	1366	(70.0)
4-9	250	(26.2)	255	(25.6)	505	(25.9)
10+	36	(3.8)	44	(4.4)	80	(4.1)
Type of Surgery						
Lumpectomy + AD	438	(45.8)	446	(44.8)	884	(45.3)
Modified Radical	518	(54.2)	549	(55.2)	1067	(54.7)
Estrogen Receptor						
Negative or Borderline	323	(33.8)	335	(33.7)	658	(33.7)
Positive	633	(66.2)	660	(66.3)	1293	(66.3)
Progesterone Receptor						
Negative or Borderline	375	(39.2)	406	(40.8)	781	(40.0)
Positive	581	(60.8)	589	(59.2)	1170	(60.0)
Disease-free Survival						
Event-free	534	(55.9)	568	(57.1)	1102	(56.5)
Experienced an Event	422	(44.1)	427	(42.9)	849	(43.5)
Total Person Months of Follow-up for Events	91,834.3		98,963.1		109,797.4	
Overall Survival						
Alive	667	(69.8)	704	(70.8)	1371	(70.3)
Dead	289	(30.2)	291	(29.2)	580	(29.7)
Total Person Months of Follow-up for Deaths	106,228.0		112,023.0		218,251.0	
All	956	(100.0)	995	(100.0)	1951	(100.0)